Establishes "New Jersey Right to Try-Plus Act" permitting terminally ill patients access to certain investigational and off-label treatments.

The New Jersey Right to Try-Plus Act permits terminally ill patients (with a life expectancy of 12 months or less) to access investigational treatments not yet approved by the FDA and off-label uses of FDA-approved drugs. To qualify, patients must consult a New Jersey-licensed physician who has reviewed all FDA-approved options, provide written consent, and meet specific criteria like having a terminal illness. Hospitals must provide FDA-approved drugs off-label upon request, while manufacturers may supply investigational treatments without charge or require patients to cover manufacturing costs - though insurers aren’t required to cover these expenses. The bill protects healthcare providers from liability for adverse outcomes (except in cases of gross negligence) and penalizes government officials who block access with fines or jail time.